TP53 and breast cancer: Our study revealed that miR-874 activates the p53 signalling pathway by suppressing the mevalonate pathway via the depletion of GGPP, suggesting the therapeutic potential of miR-874 for targeting the mevalonate pathway, especially in p53 WT breast cancers.